WALTHAM, Mass.–(BUSINESS WIRE)–Trinity Life Sciences, a leader in global life sciences commercialization solutions, maps out investment strategies and tactics to calibrate a patient-centric approach in rare disease in its new advisory brief. The brief outlines four pillars that focus resource allocation, improve patient care and provide differentiated patient partnership. Within the nuances of each disease, companies must effectively address challenges around identifying and treating patients
Click here to view original post